@Phantom1 I like the researched counter arguments, please keep them coming.
In this instance it does appear we aren't comparing 'apples with apples'. As others have noted, this Finnish study used a different mouse model strain. See text taken directly from the Finnish study you referenced. "The B16.F10.9/K1 clone is considerably more responsive to cancer immunotherapies than the highly immunosuppressive parental strain B16.F10.9."
You can also see from the two study controls below, the different mouse models show very different time-frames and tumour growth rates for the same reason.
B16.F10.9/K1 melanoma "or saline as a mock-treated group (Figure 5C)"
B16.F10.9 melanoma "Figure 2. Individual B16-F10 melanoma tumour growth rates in C57BL/6 mice inoculated with 2×105 cells. Time for the tumours to reach a size greater than 2000mm3 ranged from 8 to 20 days. n=20."
@Phantom1 I like the researched counter arguments, please keep...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.005(0.34%) |
Mkt cap ! $242.5M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.43 | $62.91K | 43.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 591 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.46 |
Change
-0.005 ( 0.23 %) |
||||
| Open | High | Low | Volume | ||
| $1.44 | $1.49 | $1.43 | 9034 | ||
| Last updated 13.08pm 24/05/2024 ? | |||||
| RAC (ASX) Chart |